Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 6c

H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

August 13, 2024 6:04 AM EDT

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $16.00 price target on Astria Therapeutics (NASDAQ: ATXS).

The analyst comments "Clinical development of navenibart and STAR-0310 backed by positive marks and new partners. Following favorable initial proof-of-concept data from the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215) in patients with hereditary angioedema (HAE), and pending regulatory feedback, the company plans to initiate a Phase 3 study in 1Q25, with top-line data expected by YE26. Recall, ALPHA-STAR... More